Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QGE031 dose-ranging phase II trial in adults with peanut allergy
2011-000631-92Phase 2Terminated
- Sponsor
- Novartis
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ligelizumab in peanut allergy (5 arms), sponsored by Novartis. Primary endpoint: Increase in peanut protein threshold dose inducing objective hypersensitivity reactions. Started Aug 2011; status: terminated.
02
Drugs
ligelizumab
03
Conditions
peanut allergy
Beyond the preview
Go deeper on 2011-000631-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000631-92.